Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Liabilities for 3 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • For Q4 2025, Total Liabilities fell 8.59% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $21.0 million, down 8.59%, while the annual FY2025 figure was $21.0 million, 8.59% down from the prior year.
  • Total Liabilities hit $21.0 million in Q4 2025 for Artiva Biotherapeutics, up from $19.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $174.7 million in Q1 2024 and bottomed at $19.6 million in Q3 2025.
  • Average Total Liabilities over 3 years is $65.7 million, with a median of $24.6 million recorded in 2024.
  • On a YoY basis, Total Liabilities climbed as much as 8.59% in 2025 and fell as far as 87.13% in 2025.
  • Artiva Biotherapeutics' Total Liabilities stood at $50.7 million in 2023, then plummeted by 54.77% to $22.9 million in 2024, then fell by 8.59% to $21.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $21.0 million, $19.6 million, and $20.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.